BMS-986020 sodium 是高亲和力溶血磷脂酸受体 1 (LPA1) 拮抗剂。BMS-986020 sodium 抑制胆汁酸和磷脂转运蛋白,抑制 BSEP,MRP4 和 MDR3,IC50 值分别为 4.8 μM,6.2 μM 和 7.5 μM。BMS-986020 sodium 有潜力用于特发性肺纤维化 (IPF) 的研究。 MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个...
BMS-986020 sodium 抑制胆汁酸和磷脂转运蛋白,抑制 BSEP,MRP4 和 MDR3,IC50 值分别为 4.8 μM,6.2 μM 和 7.5 μM。BMS-986020 sodium 用于治疗特发性肺纤维化 (IPF)。DMSO: 150 mg/mL (297.32 mM); H2O: < 0.1 mg/mL (insoluble) 分享给朋友 规格库存目录价 暂无牌价信息,您可以发送询价,我们会...
BMS-986020 sodium 有潜力用于特发性肺纤维化 (IPF) 的研究。 研究领域:GPCR/G Protein 作用靶点:LPL Receptor In Vitro: BMS-986020 sodium (0.1-10 nM; pre-incubated) concentration-dependent displacement of [18F]BMT-083133 binding is observed in LPA1+ cells and lung sections. At 0.1 nM, the ...
pulmonaryLysophospholipid ReceptorLPLReceptorLPL ReceptorLPLLPAReceptorLPA1LPA ReceptorIPFInhibitorinhibitidiopathicfibrosisBMS-986020BMS 986020autoradiographyARGAM-152AM 152Related Tags: buy BMS-986020 | purchase BMS-986020 | BMS-986020 cost | order BMS-986020 | BMS-986020 chemical structure | BMS-986020 fo...
A phase 2 trial (NCT01766817) showed thattwice-daily treatment with BMS-986020, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, significantly decreased the slope of forced vital capacity (FVC) decline over 26weeks compared with placebo in patients with IPF. This analysis aimed to better...
BMS-986020 sodium 是高亲和力的溶血磷脂酸受体 1 (LPA1) 拮抗剂,能够抑制胆汁酸和磷脂转运蛋白,并抑制 BSEP (IC50: 4.8 μM),MRP4 (IC50: 6.2 μM) 和 MDR3 (IC50: 7.5 μM)。BMS-986020 sodium 表现出特发性肺纤维化 (IPF) 的研究潜力。
Safety and efficacy of BMS-986020, a high-affinity LPA1antagonist, was assessed vs?placebo in a phase 2 study in patients with IPF. MethodsIM136003 was a phase 2, parallel-arm, multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-90%; diffusing ...